Anlotinib Not Yet Recruiting Phase 4 Trials for Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT03799601Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC